A population analysis of VEGF transgene expression and secretion

The induction of therapeutic angiogenesis with gene therapy approaches has received considerable interest and some limited clinical success. A major drawback to this approach is a lack of understanding of the pharmacokinetics of therapeutic protein delivery. This has become increasingly more relevant as recent studies have illustrated a defined therapeutic window for angiogenic protein secretion into the local microenvironment. For cell based gene therapies, with cells widely distributed throughout the tissue, this implies that any individual cell must attain a specific secretion rate to produce a local angiogenic response. Here we report a reproducible technique enabling the study of growth factor secretion from individual cells following transient plasmid transfection. We demonstrate significant variability in single cell vascular endothelial growth factor (VEGF) secretion with the majority of total protein secretion arising from a small subpopulation of transfected cells. We demonstrate that VEGF secretion is linearly correlated to intracellular plasmid copy number and protein secretion does not appear to reach saturation within the cell population. The selection of gene therapy approaches that optimize individual cell secretion profiles may be essential for the development of effective gene therapies. Biotechnol. Bioeng. © 2008 Wiley Periodicals, Inc.

[1]  F. Torti,et al.  Recombinant ferritin: modulation of subunit stoichiometry in bacterial expression systems. , 1997, Protein engineering.

[2]  Diane J Burgess,et al.  Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[3]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[4]  J. Isner,et al.  Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[5]  H. Mizuguchi,et al.  IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  C. Ricordi,et al.  Transplantation: current developments and future directions; the future of clinical islet transplantation as a cure for diabetes. , 2008, Frontiers in bioscience : a journal and virtual library.

[7]  D. Stewart,et al.  Microvascular Regeneration in Established Pulmonary Hypertension by Angiogenic Gene Transfer Materials and Methods Cell Isolation and Culture , 2022 .

[8]  H. Blau,et al.  Critical role of microenvironmental factors in angiogenesis , 2005, Current atherosclerosis reports.

[9]  Todd D. Giorgio,et al.  Transfection by Cationic Liposomes Using Simultaneous Single Cell Measurements of Plasmid Delivery and Transgene Expression* , 1997, The Journal of Biological Chemistry.

[10]  Y. Yoon,et al.  Therapeutic myocardial angiogenesis with vascular endothelial growth factors , 2004, Molecular and Cellular Biochemistry.

[11]  G. Rubanyi,et al.  The future of human gene therapy. , 2001, Molecular aspects of medicine.

[12]  Doris A Taylor,et al.  Cell–based cardiovascular repair , 2005, Basic Research in Cardiology.

[13]  F. Wurm,et al.  Transfer of high copy number plasmid into mammalian cells by calcium phosphate transfection. , 2001, Gene.

[14]  B. Oh,et al.  Two‐promoter vector is highly efficient for overproduction of protein complexes , 2004, Protein science : a publication of the Protein Society.

[15]  D. Dean,et al.  Nonviral Gene Transfer Strategies for the Vasculature , 2002, Microcirculation.

[16]  M. D. Brown,et al.  Gene delivery with synthetic (non viral) carriers. , 2001, International journal of pharmaceutics.

[17]  D. Stewart,et al.  Cell therapy for pulmonary hypertension: what is the true potential of endothelial progenitor cells? , 2004, Circulation.

[18]  M. Chopp,et al.  Therapeutic Benefit of Intravenous Administration of Bone Marrow Stromal Cells After Cerebral Ischemia in Rats , 2001, Stroke.

[19]  D. Mooney,et al.  Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.

[20]  Shay Soker,et al.  Characterization of Novel Vascular Endothelial Growth Factor (VEGF) Receptors on Tumor Cells That Bind VEGF via Its Exon 7-encoded Domain (*) , 1996, The Journal of Biological Chemistry.

[21]  J. Isner,et al.  Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. , 1995, Circulation.

[22]  D. Nolte,et al.  Restoration of blood flow and evaluation of corresponding angiogenic events by scanning electron microscopy after a single dose of VEGF in a model of peripheral vascular disease , 2004, Angiogenesis.

[23]  Amit N. Patel,et al.  Cell based approaches for myocardial regeneration and artificial myocardium. , 2007, Current stem cell research & therapy.

[24]  J. Isner,et al.  Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. , 1996, Circulation.

[25]  Yasuo Shinohara,et al.  Quantitative Analysis of Correlation Between Number of Nuclear Plasmids and Gene Expression Activity After Transfection with Cationic Liposomes , 2002, Pharmaceutical Research.

[26]  H. Blau,et al.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. , 2004, The Journal of clinical investigation.

[27]  J. Folkman,et al.  Vasculogenesis, Angiogenesis, and Growth Factors: Ephrins Enter the Fray at the Border , 1998, Cell.

[28]  D. Stewart,et al.  Cell-Based Gene Transfer of Vascular Endothelial Growth Factor Attenuates Monocrotaline-Induced Pulmonary Hypertension , 2001, Circulation.

[29]  D H Kohn,et al.  Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. , 2000, Biomaterials.

[30]  A. Secchi,et al.  Pancreatic islet cell transplant for treatment of diabetes. , 2007, Endocrinology and metabolism clinics of North America.

[31]  Holger Gerhardt,et al.  Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis , 2007, Nature.

[32]  Takayuki Asahara,et al.  Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb , 1996, The Lancet.

[33]  J. Isner,et al.  Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. , 1995, Journal of vascular surgery.

[34]  Holger Gerhardt,et al.  Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. , 2002, Genes & development.

[35]  N. Ferrara Molecular and biological properties of vascular endothelial growth factor , 1999, Journal of Molecular Medicine.

[36]  Wong,et al.  Biological barriers to cellular delivery of lipid-based DNA carriers. , 1999, Advanced drug delivery reviews.

[37]  Bart Landuyt,et al.  Vascular Endothelial Growth Factor and Angiogenesis , 2004, Pharmacological Reviews.